1. Develop robust recommendations for policy changes that will increase access to appropriate migraine treatments through community pharmacy. 
2. Secure consensus from key stakeholders at both a national and local level. 
3. Advocate for change, identifying potential champions across both the political and public spheres. 

Benefits to patients
Greater awareness among policy makers of the need to prioritise migraine treatment and management, and the benefits of doing this in the community via community pharmacy.

Benefits to the NHS/UK Government
Better management of migraine in community pharmacy (and the ability of pharmacists to manage more cases) will support NHS drives to reduce costs and waiting times in secondary care, and to help free up capacity in general practice. The approach supports the UK Government’s desired ‘shift to the left’ to enable more care to be provided in community settings. 

Benefits to the Company Chemists' Association
Increased options for the management of migraine in community pharmacy will benefit the Company Chemists' Association members, who will benefit from an increase in services available to provide to eligible patients.

Benefits to Pfizer
Greater awareness of the important role of community pharmacy in the long-term management of migraine supports Pfizer’s business objectives around migraine management in the community and supporting a robust migraine treatment environment.. 

• Position migraine as a natural expansion route for Pharmacy First care across England. 
• Identify potential challenges and consider practical routes to mitigate these, developing robust proposals to secure policy change to support the future role of community pharmacy in migraine management. 
• Work to secure consensus across key health and political stakeholders to create momentum for change.